New Guidelines Issued for Anticoagulant Prophylaxis for Pediatric VTE

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on April 15, 2026.

via HealthDay

WEDNESDAY, April 15, 2026 -- Recommendations for anticoagulant prophylaxis for pediatric patients at risk for venous thromboembolism (VTE) are presented in clinical practice guidelines issued by the American Society of Hematology and the International Society on Thrombosis and Hemostasis. The guidelines were published online April 8 in Blood Advances.

Marisol Betensky, M.D., M.P.H., from Johns Hopkins All Children's Hospital in St. Petersburg, Florida, and colleagues developed evidence-based guidelines to support patients and health care professionals regarding decisions about anticoagulant prophylaxis for prevention of VTE in pediatric patients. A multidisciplinary guideline panel was formed that included one patient representative.

Twelve recommendations were agreed on by the panel. Conditional recommendations suggesting no anticoagulant prophylaxis were issued for pediatric patients with solid cancer, trauma, or critical illness. Conditional recommendations suggesting anticoagulant prophylaxis were issued for pediatric patients with antiphospholipid antibody syndrome or those on long-term total parenteral nutrition. For children with leukemia/lymphoblastic lymphoma, the authors recommend use of anticoagulant prophylaxis should be based on individual assessment for the risk for thrombosis and bleeding and patients' values and preferences. No anticoagulant prophylaxis was suggested for children with central venous access devices or for children undergoing noncardiac surgery.

"Prior to the development of these clinical guidelines, much of the data we referenced for VTE prevention in pediatric patients was extrapolated from adults, whose risk profiles are generally less varied and complex," Betensky said in a statement. "These guidelines provide physicians with an evidence-based framework to make decisions about VTE prophylaxis for children.”

Several authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-04-16 02:10

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords